Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2025

Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?

Introduction and first vote

Date

27 Mar 2025

Session

Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Myung-Ju Ahn

Authors

M. Ahn

Author affiliations

  • Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul/KR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

The time for TKI combinations is now

Presenter: Antonio Passaro

Session: Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?

Resources:

Slides

Webcast

Second vote and conclusions/discussion

Presenter: Myung-Ju Ahn

Session: Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.